CombinatoRx reports CRx-102 leads to lower pain in patients with osteoarthritis of the hand

By Ted A. Knutson

Washington, Jan. 30 - CombinatoRx, Inc. announced Monday positive preliminary results of its randomized, blinded, placebo-controlled phase 2 clinical trial of CRx-102 in patients with osteoarthritis of the hand.

The study met its primary endpoint of improvement in the Auscan visual analogue pain scale.

Analysis of the primary endpoint shows mean change from baseline in the CRx-102 group was minus 102.4 mm for a 33% improvement in pain compared to mean change from baseline in the placebo group of minus 30.9 mm for a 10% improvement.

This improvement in pain was statistically significant with p=0.006.

CRx-102 is a novel synergistic combination drug candidate discovered and developed by CombinatoRx using CombinatoRx's combination high throughput screening technology.

CRx-102 was generally well tolerated and there were no serious adverse events reported. The most common adverse events observed with CRx-102 were headache and nausea, known side effects of one of the two components.

CRx-102 is under study in two further phase 2 clinical trials in patients with rheumatoid arthritis and in a systemic inflammatory disease model, chronic adult periodontitis.

The drug is one of a portfolio of seven product candidates that CombinatoRx is testing in phase 2 clinical trials.

Boston-based CombinatoRx is a biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.